Related content

Bayesian Calibration of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Carbaryl Cholinesterase Inhibition

By Nong Andy   Tan Yu-Mei   Krolski Michael   Wang Jiansuo   Lunchick Curt   Conolly Rory   Clewell Harvey  

Journal of Toxicology and Environmental Health, Vol. 71, Iss. 20, 2008-01 ,pp. : 1363-1381

Taylor & Francis Ltd

Access to resources Recommend Favorite

Population Pharmacokinetic/Pharmacodynamic Analyses as the Basis for Dosing of Therapeutic Monoclonal Antibodies

By Meibohm Bernd  

Clinical Pharmacokinetics, Vol. 50, Iss. 12, 2011-12 ,pp. : 823-824

Adis International

Access to resources Recommend Favorite

Validation of a population pharmacokinetic/pharmacodynamic model for 5 -reductase inhibitors

By Trouw R.A.J.   De Wit M.J.   Olsson Gisleskog P.   Hermann D.   Hammarlund-Udenaes M.   Karlsson M.O.  

European Journal of Pharmaceutical Sciences, Vol. 8, Iss. 4, 1999-08 ,pp. : 291-299

Elsevier

Access to resources Recommend Favorite

Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment

By Harrold John   Abraham Anson  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 41, Iss. 2, 2014-04 ,pp. : 141-151

Springer Publishing Company

Access to resources Recommend Favorite

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

By Gibiansky Leonid   Gibiansky Ekaterina  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 7, 2009-07 ,pp. : 803-812

Informa Healthcare

Access to resources Recommend Favorite